Beta‐catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics

Medulloblastoma is the most frequent malignant paediatric brain tumour. The activation of the Wnt/β‐catenin pathway occurs in 10‐15% of medulloblastomas and has been recently described as a marker for favourable patient outcome. We report a series of 72 paediatric medulloblastomas evaluated for β‐catenin protein expression, CTNNB1 mutations, and comparative genomic hybridization. Gene expression profiles were also available in a subset of 40 cases. Immunostaining of β‐catenin showed extensive nuclear staining (>50% of the tumour cells) in six cases and focal nuclear staining (<10% of cells) in three cases. The other cases either exhibited a signal strictly limited to the cytoplasm (58 cases) or were negative (five cases). CTNNB1 mutations were detected in all β‐catenin extensively nucleopositive cases. The expression profiles of these cases documented strong activation of the Wnt/β‐catenin pathway. Remarkably, five out of these six tumours showed a complete loss of chromosome 6. In contrast, cases with focal nuclear β‐catenin staining, as well as tumours with negative or cytoplasmic staining, never demonstrated CTNNB1 mutation, Wnt/β‐catenin pathway activation or chromosome 6 loss. Patients with extensive nuclear staining were significantly older at diagnosis and were in continuous complete remission after a mean follow‐up of 75.7 months (range 27.5–121.2 months) from diagnosis. All three patients with focal nuclear staining of β‐catenin died within 36 months from diagnosis. Altogether, these data confirm and extend previous observations that CTNNB1‐mutated tumours represent a distinct molecular subgroup of medulloblastomas with favourable outcome, indicating that therapy de‐escalation should be considered. International consensus on the definition criteria of this distinct medulloblastoma subgroup should be achieved. Copyright © 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

[1]  Dirk Troost,et al.  Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features , 2008, PloS one.

[2]  G. Cavet,et al.  Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL , 2007, Nature Medicine.

[3]  W. Hartmann,et al.  Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91 , 2007, Clinical Cancer Research.

[4]  Roger E. Taylor,et al.  Nodule Formation and Desmoplasia in Medulloblastomas—Defining the Nodular/Desmoplastic Variant and Its Biological Behavior , 2007, Brain pathology.

[5]  Webster K. Cavenee,et al.  WHO Classification of Tumours of the Central Nervous System. 4th Ed. , 2007 .

[6]  D. Ellison,et al.  Wnt/Wingless Pathway Activation and Chromosome 6 Loss Characterise a Distinct Molecular Sub-Group of Medulloblastomas Associated with a Favourable Prognosis , 2006, Cell cycle.

[7]  A. Tubiana,et al.  Treatment of high risk medulloblastomas in children above the age of 3 years: a SFOP study. , 2006, European journal of cancer.

[8]  H. Heinzl,et al.  Histopathological prognostic factors in medulloblastoma: high expression of survivin is related to unfavourable outcome. , 2006, European journal of cancer.

[9]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[10]  P. Kleihues,et al.  Stratification of medulloblastoma on the basis of histopathological grading , 2006, Acta Neuropathologica.

[11]  T. Curran,et al.  Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Axel Benner,et al.  Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Claire L Weston,et al.  beta-Catenin status predicts a favorable outcome in childhood medulloblastoma: the United Kingdom Children's Cancer Study Group Brain Tumour Committee. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  Olivier Delattre,et al.  Two types of chromosome 1p losses with opposite significance in gliomas , 2005, Annals of neurology.

[16]  D. Frappaz,et al.  Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. , 2005, The Lancet. Oncology.

[17]  D. Frappaz,et al.  Standard-risk medulloblastoma treated by adjuvant chemotherapy followed by reduced-dose craniospinal radiation therapy: a French Society of Pediatric Oncology Study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  H. Clevers,et al.  Wnt signalling in stem cells and cancer , 2005, Nature.

[19]  T. Pietsch,et al.  Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. , 2005, The New England journal of medicine.

[20]  M. Ilyas,et al.  Wnt signalling and the mechanistic basis of tumour development , 2005, The Journal of pathology.

[21]  J. Grill,et al.  Conformal radiotherapy, reduced boost volume, hyperfractionated radiotherapy, and online quality control in standard-risk medulloblastoma without chemotherapy: results of the French M-SFOP 98 protocol. , 2003, International journal of radiation oncology, biology, physics.

[22]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[23]  D. Ellison,et al.  Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients , 2004, Clinical Cancer Research.

[24]  Rafael A. Irizarry,et al.  A Model-Based Background Adjustment for Oligonucleotide Expression Arrays , 2004 .

[25]  D. Ellison,et al.  Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non‐Desmoplastic Medulloblastomas , 2003, Journal of neuropathology and experimental neurology.

[26]  Akira Kikuchi,et al.  Tumor formation by genetic mutations in the components of the Wnt signaling pathway , 2003, Cancer science.

[27]  L. Clegg,et al.  Incidence and trends in pediatric malignancies medulloblastoma/primitive neuroectodermal tumor: a SEER update. Surveillance Epidemiology and End Results. , 2002, Medical and pediatric oncology.

[28]  David H Rowitch,et al.  Medulloblastoma: a problem of developmental biology. , 2002, Cancer cell.

[29]  P. Polakis Wnt signaling and cancer. , 2000, Genes & development.

[30]  P. Burger,et al.  Nuclear Localization and Mutation of β‐Catenin in Medulloblastomas , 2000 .

[31]  P. Burger,et al.  Nuclear localization and mutation of beta-catenin in medulloblastomas. , 2000, Journal of neuropathology and experimental neurology.

[32]  M. Buendia,et al.  Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. , 1999, The American journal of pathology.

[33]  Jan Bayer,et al.  Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity , 1999, Oncogene.

[34]  L. Rorke,et al.  Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Raffel,et al.  Sporadic Medulloblastomas Contain Oncogenic β-Catenin Mutations , 1998 .

[36]  C. Raffel,et al.  Sporadic medulloblastomas contain oncogenic beta-catenin mutations. , 1998, Cancer research.

[37]  R. Barnard,et al.  The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.